Which has better earnings and valuation, ALMS or MGNX?

MacroGenics has higher revenue and earnings than Alumis. MacroGenics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $24.05M 32.94 -$243.32M -$3.86 N/A MacroGenics $149.50M 1.38 -$74.62M -$0.22 N/A

Is ALMS or MGNX more profitable?

MacroGenics has a net margin of -8.70% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -5,933.46% -93.15% -74.50% MacroGenics -8.70% -109.26% -18.70%

Does the media favor ALMS or MGNX?

In the previous week, Alumis had 2 more articles in the media than MacroGenics. MarketBeat recorded 6 mentions for Alumis and 4 mentions for MacroGenics. Alumis' average media sentiment score of 0.68 beat MacroGenics' score of 0.48 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MGNX or GLUE?

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than MacroGenics. MarketBeat recorded 5 mentions for Monte Rosa Therapeutics and 4 mentions for MacroGenics. Monte Rosa Therapeutics' average media sentiment score of 0.85 beat MacroGenics' score of 0.48 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ODTX or MGNX?

In the previous week, Odyssey Therapeutics had 2 more articles in the media than MacroGenics. MarketBeat recorded 6 mentions for Odyssey Therapeutics and 4 mentions for MacroGenics. Odyssey Therapeutics' average media sentiment score of 0.60 beat MacroGenics' score of 0.48 indicating that Odyssey Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Odyssey Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MGNX or ABUS?

In the previous week, MacroGenics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for MacroGenics and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.55 beat MacroGenics' score of 0.48 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MacroGenics (MGNX) Competitors

$3.25 -0.12 (-3.56%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$3.24 0.00 (-0.15%)

As of 10/16/2026 07:30 PM Eastern

Compare

MGNX vs. JBIO, ALMS, GLUE, ODTX, and ABUS

Should you buy MacroGenics stock or one of its competitors? MacroGenics's main competitors and comparable companies include Jade Biosciences (JBIO), Alumis (ALMS), Monte Rosa Therapeutics (GLUE), Odyssey Therapeutics (ODTX), and Arbutus Biopharma (ABUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MacroGenics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

96.9% of MacroGenics shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by insiders. Comparatively, 13.6% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Jade Biosciences has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

MacroGenics has higher revenue and earnings than Jade Biosciences. MacroGenics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A
MacroGenics	$149.50M	1.38	-$74.62M	-$0.22	N/A

Jade Biosciences has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Jade Biosciences' return on equity of -49.11% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-49.11%	-45.62%
MacroGenics	-8.70%	-109.26%	-18.70%

In the previous week, MacroGenics had 4 more articles in the media than Jade Biosciences. MarketBeat recorded 4 mentions for MacroGenics and 0 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.82 beat MacroGenics' score of 0.48 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Jade Biosciences	Very Positive
MacroGenics	Neutral

Jade Biosciences currently has a consensus target price of $51.75, indicating a potential upside of 284.19%. MacroGenics has a consensus target price of $6.33, indicating a potential upside of 94.87%. Given Jade Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Jade Biosciences is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Jade Biosciences beats MacroGenics on 9 of the 15 factors compared between the two stocks.

How does MacroGenics compare to Alumis?

Alumis (NASDAQ:ALMS) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

In the previous week, Alumis had 2 more articles in the media than MacroGenics. MarketBeat recorded 6 mentions for Alumis and 4 mentions for MacroGenics. Alumis' average media sentiment score of 0.68 beat MacroGenics' score of 0.48 indicating that Alumis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MacroGenics has a net margin of -8.70% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
MacroGenics	-8.70%	-109.26%	-18.70%

Alumis currently has a consensus target price of $33.27, suggesting a potential upside of 443.67%. MacroGenics has a consensus target price of $6.33, suggesting a potential upside of 94.87%. Given Alumis' stronger consensus rating and higher probable upside, equities analysts plainly believe Alumis is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

96.9% of MacroGenics shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Comparatively, 13.6% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MacroGenics has higher revenue and earnings than Alumis. MacroGenics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	32.94	-$243.32M	-$3.86	N/A
MacroGenics	$149.50M	1.38	-$74.62M	-$0.22	N/A

Alumis has a beta of -0.38, suggesting that its share price is 138% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Summary

Alumis beats MacroGenics on 9 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Monte Rosa Therapeutics?

MacroGenics (NASDAQ:MGNX) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

MacroGenics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

Monte Rosa Therapeutics has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.38	-$74.62M	-$0.22	N/A
Monte Rosa Therapeutics	$123.67M	6.72	-$38.63M	-$1.76	N/A

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than MacroGenics. MarketBeat recorded 5 mentions for Monte Rosa Therapeutics and 4 mentions for MacroGenics. Monte Rosa Therapeutics' average media sentiment score of 0.85 beat MacroGenics' score of 0.48 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MacroGenics currently has a consensus price target of $6.33, indicating a potential upside of 94.87%. Monte Rosa Therapeutics has a consensus price target of $26.67, indicating a potential upside of 173.79%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Monte Rosa Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MacroGenics has a net margin of -8.70% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

Summary

Monte Rosa Therapeutics beats MacroGenics on 11 of the 17 factors compared between the two stocks.

How does MacroGenics compare to Odyssey Therapeutics?

Odyssey Therapeutics (NASDAQ:ODTX) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Odyssey Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -8.70%. Odyssey Therapeutics' return on equity of 0.00% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Odyssey Therapeutics	N/A	N/A	N/A
MacroGenics	-8.70%	-109.26%	-18.70%

96.9% of MacroGenics shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Odyssey Therapeutics has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A
MacroGenics	$149.50M	1.38	-$74.62M	-$0.22	N/A

Odyssey Therapeutics presently has a consensus price target of $35.33, suggesting a potential upside of 105.79%. MacroGenics has a consensus price target of $6.33, suggesting a potential upside of 94.87%. Given Odyssey Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Odyssey Therapeutics is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Odyssey Therapeutics had 2 more articles in the media than MacroGenics. MarketBeat recorded 6 mentions for Odyssey Therapeutics and 4 mentions for MacroGenics. Odyssey Therapeutics' average media sentiment score of 0.60 beat MacroGenics' score of 0.48 indicating that Odyssey Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Odyssey Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Odyssey Therapeutics beats MacroGenics on 9 of the 13 factors compared between the two stocks.

How does MacroGenics compare to Arbutus Biopharma?

MacroGenics (NASDAQ:MGNX) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Arbutus Biopharma has a net margin of 84.22% compared to MacroGenics' net margin of -8.70%. Arbutus Biopharma's return on equity of 90.98% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-8.70%	-109.26%	-18.70%
Arbutus Biopharma	84.22%	90.98%	82.34%

MacroGenics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

MacroGenics presently has a consensus price target of $6.33, indicating a potential upside of 94.87%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential upside of 18.48%. Given MacroGenics' higher possible upside, equities research analysts plainly believe MacroGenics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arbutus Biopharma has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.38	-$74.62M	-$0.22	N/A
Arbutus Biopharma	$14.08M	59.38	-$33.50M	$0.79	5.34

In the previous week, MacroGenics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for MacroGenics and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.55 beat MacroGenics' score of 0.48 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arbutus Biopharma beats MacroGenics on 10 of the 16 factors compared between the two stocks.

Get MacroGenics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGNX vs. The Competition

Export

Metric	MacroGenics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$207.03M	$3.90B	$7.44B	$12.68B
Dividend Yield	N/A	3.65%	2.50%	32.09%
P/E Ratio	-14.77	9.76	194.37	19.23
Price / Sales	1.38	1,172.38	570.76	76.91
Price / Cash	N/A	117.89	74.88	50.51
Price / Book	3.69	15.94	10.31	5.85
Net Income	-$74.62M	-$22.69M	$3.51B	$381.63M
7 Day Performance	-13.10%	-8.71%	-5.47%	-5.04%
1 Month Performance	-21.31%	-15.43%	-9.66%	-7.99%
1 Year Performance	96.97%	1.39%	0.73%	-5.68%

MacroGenics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGNX MacroGenics	1.7723 of 5 stars	$3.25 -3.6%	$6.33 +94.9%	+92.3%	$207.03M	$149.50M	N/A	293	News Coverage
JBIO Jade Biosciences	1.6713 of 5 stars	$13.41 -4.2%	$51.75 +285.9%	+37.7%	$852.84M	N/A	N/A	55
ALMS Alumis	4.014 of 5 stars	$6.56 -7.1%	$33.27 +407.2%	+32.8%	$849.06M	$24.05M	N/A	239	Positive News Short Interest Increase
GLUE Monte Rosa Therapeutics	2.6224 of 5 stars	$9.89 -6.0%	$26.67 +169.6%	-5.5%	$843.75M	$28.73M	N/A	173
ODTX Odyssey Therapeutics	3.4511 of 5 stars	$17.24 -5.6%	$35.33 +104.9%	N/A	$828.55M	N/A	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGNX) was last updated on 10/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MacroGenics (MGNX) Competitors

MGNX vs. JBIO, ALMS, GLUE, ODTX, and ABUS

How does MacroGenics compare to Jade Biosciences?

Summary

How does MacroGenics compare to Alumis?

Summary

How does MacroGenics compare to Monte Rosa Therapeutics?

Summary

How does MacroGenics compare to Odyssey Therapeutics?

Summary

How does MacroGenics compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MacroGenics (MGNX) Competitors

MGNX vs. JBIO, ALMS, GLUE, ODTX, and ABUS

How does MacroGenics compare to Jade Biosciences?

Do insiders & institutionals have more ownership in JBIO or MGNX?

Which has more risk and volatility, JBIO or MGNX?

Which has preferable valuation & earnings, JBIO or MGNX?

Is JBIO or MGNX more profitable?

Does the media favor JBIO or MGNX?

Do analysts recommend JBIO or MGNX?

Summary

How does MacroGenics compare to Alumis?

Does the media favor ALMS or MGNX?

Is ALMS or MGNX more profitable?

Do analysts rate ALMS or MGNX?

Do institutionals & insiders believe in ALMS or MGNX?

Which has better earnings and valuation, ALMS or MGNX?

Which has more risk and volatility, ALMS or MGNX?

Summary

How does MacroGenics compare to Monte Rosa Therapeutics?

Which has more risk & volatility, MGNX or GLUE?

Which has better valuation and earnings, MGNX or GLUE?

Does the media refer more to MGNX or GLUE?

Do analysts rate MGNX or GLUE?

Do institutionals and insiders have more ownership in MGNX or GLUE?

Is MGNX or GLUE more profitable?

Summary

How does MacroGenics compare to Odyssey Therapeutics?

Is ODTX or MGNX more profitable?

Do institutionals & insiders hold more shares of ODTX or MGNX?

Which has preferable earnings and valuation, ODTX or MGNX?

Do analysts prefer ODTX or MGNX?

Does the media favor ODTX or MGNX?

Summary

How does MacroGenics compare to Arbutus Biopharma?

Do institutionals and insiders have more ownership in MGNX or ABUS?

Is MGNX or ABUS more profitable?

Which has more volatility & risk, MGNX or ABUS?

Do analysts rate MGNX or ABUS?

Which has higher earnings and valuation, MGNX or ABUS?

Does the media refer more to MGNX or ABUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools